4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine has been researched along with cocaine in 1 studies
| Studies (4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine) | Trials (4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine) | Recent Studies (post-2010) (4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine) | Studies (cocaine) | Trials (cocaine) | Recent Studies (post-2010) (cocaine) |
|---|---|---|---|---|---|
| 9 | 0 | 1 | 32,461 | 1,096 | 9,400 |
| Protein | Taxonomy | 4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine (IC50) | cocaine (IC50) |
|---|---|---|---|
| Amyloid-beta precursor protein | Homo sapiens (human) | 0.338 | |
| Fatty acid-binding protein, heart | Homo sapiens (human) | 0.367 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0855 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0855 | |
| D | Rattus norvegicus (Norway rat) | 5.7544 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 5.7544 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 5.7544 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 5.7544 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.2861 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.4321 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0855 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.5442 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.8885 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.3796 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 5.541 | |
| Sodium-dependent dopamine transporter | Mus musculus (house mouse) | 0.2 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 1.05 | |
| Transporter | Rattus norvegicus (Norway rat) | 3.2277 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castagnoli, N; Dormehl, IC; Hugo, N; Keeve, R; Müller-Gärtner, HW; Neumeyer, JL; Oliver, DW; Rossouw, NT; Van der Schyf, CJ | 1 |
1 other study(ies) available for 4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine and cocaine
| Article | Year |
|---|---|
Effect of the haloperidol tetrahydropyridine metabolite 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6- tetrahydropyridine on dopamine receptor and transporter binding. A nonhuman primate 123I-iodobenzamide and 2 beta-carbomethoxy-3 beta-(4-
Topics: Animals; Antipsychotic Agents; Benzamides; Brain; Carrier Proteins; Cocaine; Dopamine; Dopamine Plasma Membrane Transport Proteins; Haloperidol; Iodine Radioisotopes; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Papio; Pyrrolidines; Receptors, Dopamine; Tomography, Emission-Computed, Single-Photon | 1997 |